Travel in patients receiving TNF-alpha inhibitors

Travel Medicine and Infectious Disease

Volumn 3, Issue 2, 2005, Pages 105-109

  Orenstein, Robert ^a  

^a Mayo Clinic   (United States)

Author keywords

Infectious complications; TNF inhibitors; Travel

Indexed keywords

ADALIMUMAB; ANTIHISTAMINIC AGENT; COTRIMOXAZOLE; ETANERCEPT; INFLIXIMAB; PNEUMOCOCCUS VACCINE; PROTON PUMP INHIBITOR; TUMOR NECROSIS FACTOR ANTIBODY; TYPHOID VACCINE; YELLOW FEVER VACCINE;

BACTERIAL INFECTION; CHRONIC INFLAMMATION; DRUG HALF LIFE; HUMAN; INFECTIOUS COMPLICATION; INFLAMMATORY DISEASE; LIFESTYLE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOCIAL MEDICINE; TRAVEL; VIRUS INFECTION;

EID: 14944345442     PISSN: 14778939     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tmaid.2004.08.002     Document Type: Article

References (25)

1. A. Virk Medical advice for international travelers Mayo Clin Proc 76 2001 831-840
2. E.T. Ruan K.C. Kaine Health advice for immunization of travelers N Engl J Med 342 2004 1716-1725
3. P.E. Lipsky D.M. van der Heijde E.W. St. Clair et al. Infliximab and methotrexate in the treatment of rheumatoid arthritris. Anti-tumor necrosis factor trial in rheumatoid arthritis with concomittant therapy (ATTRACT Study Group) N Engl J Med 343 2000 1594-1602
4. J. Braun J. Brandt J. Listing et al. Treatment of active ankylosing spondylitis with infliximab: A randomized controlled multicenter trial Lancet 359 2002 1187-1193
5. W.J. Sanborn S.B. Hanauer Infliximab in the treatment of Crohn's disease: A users guide for clinicians Am J Gastroenterol 97 2002 2962-2972
6. B. Foxwell E. Andreakos M. Feldmann C. Smith M. Conron Prospects for the development of small molecular weight compounds to replace anti-tumor necrosis factor biological agents Ann Rheum Dis 62 S2 2003 ii90-ii99
7. G. Cunane M. Doran B. Bresnihan Infliximab and biological therapy in rheumatoid arthritis Best Pract Res Clin Rheum 17 2003 345-363
8. S. Ehlers Role of tumor necrosis factor (TNF) in host defense against tuberculosis: Implications for immunotherapies targeting TNF Ann Rheum Dis 62 Suppl. II 2003 ii37-ii42
9. D. Khanna M. McMahon D.E. Furst Safety of tumour necrosis factor-alpha antagonists Drug Safety 27 2004 307-324
10. K. Leder V. Sundararajan L. Weld P. Pandey G. Brown J. Torresi for the Geosentinel Surveillance Group Respiratory tract infections in travelers:a review of the GeoSentinel Surveillance Network Clin Infect Dis 36 2003 399-406
11. A.K. Mohan T.R. Cote J.N. Siegel M.M. Braun Infectious complications of biologic treatments of rheumatoid arthritis Curr Opin Rheumatol 15 2003 179-184
12. M.G. Netea T. Radstake L.A. Joosten J.W.M. van der Meer P. Barrera B.J. Kullberg Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy. Association with decreased interferon gamma production and Toll-like receptor 4 expression Arthritis Rheum 48 2003 1853-1857
13. H.L. Rieder Risk of travel associated tuberculosis Clin Infect Dis 33 2001 1393-1396
14. J. Keane S. Gershon R.P. Wise et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha neutralizing agent N Engl J Med 345 2001 1098-2103
15. R.S. Wallis M.S. Broder J.Y. Wong M.E. Hanson D.O. Beenhouwer Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 2004 1261-1265
16. R. Long M. Gardam Tumor necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection CMAJ 168 2003 1153-1156
17. J.J. Gomez-Reino L. Carmona V.V. Rodriguez et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active surveillance report Arthritis Rheum 48 2003 2122-2127
18. A. Honstettre E. Ghigo A. Moynault et al. Lipopolysaccharide from Coxiella burnetti is involved in bacterial phagocytosis, filamentous actin reorganization, and inflammatory responses through Toll-like receptor 4 J Immunol 172 2004 3695-3703
19. A.Q. Khan Y. Shen Z.Q. Wu T.A. Wynn C.M. Snapper Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptococcus pneumoniae Infect Immunol 70 2002 749-761
20. O. Elkayam D. Caspi T. Reitblatt D. Charboneau J.B. Rubins The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis Semin Arthritis Rheum 33 2004 283-288
21. O. Elkayam D. Paran D. Caspi et al. Immunogenicity and safety of pneumococcal vaccination in patients with rheumatoid arthritis or systemic lupus erythematosus Clin Infect Dis 34 2002 147-153
22. Enbrel package insert. October 1, 2003.
23. S. Looareesuwan L. Sjostrom S. Krudsood et al. Polyclonal anti-tumor necrosis factor alpha Fab used as an ancillary treatment for severe malaria Am J Trop Med Hyg 61 1999 26-33
24. A.A. Panackal R.A. Hajjeh M.S. Cetron D.W. Warnock Fungal infections among returning travelers Clin Infect Dis 35 2002 1088-1095
25. W.S. Mow M.T. Abreu-Martin K.A. Papadakis H.E. Pitchon S.R. Targan E.A. Vasiliauskas High incidence of anergy in inflammatory bowel disease patients limits the usefulness of PPD screening before infliximab therapy Clin Gastroenterol Hepatol 2 2004 309-313